AR069568A1 - MALARIA VACCINE USING RECOMBINANT ADENOVIRAL VECTORS - Google Patents

MALARIA VACCINE USING RECOMBINANT ADENOVIRAL VECTORS

Info

Publication number
AR069568A1
AR069568A1 ARP080105281A ARP080105281A AR069568A1 AR 069568 A1 AR069568 A1 AR 069568A1 AR P080105281 A ARP080105281 A AR P080105281A AR P080105281 A ARP080105281 A AR P080105281A AR 069568 A1 AR069568 A1 AR 069568A1
Authority
AR
Argentina
Prior art keywords
viral vector
adenoviral vectors
recombinant adenoviral
malaria vaccine
seq
Prior art date
Application number
ARP080105281A
Other languages
Spanish (es)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR069568A1 publication Critical patent/AR069568A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un vector adenovírico de simio deficiente de replicacion C7 que codifica una proteína que comprende la proteína CS de P. falciparum o un fragmento de la misma por ejemplo como se muestra en la SEC ID N°: 1 o la SEC ID N°: 3. También procedimientos de preparacion de dicho vector vírico y al uso del vector vírico en el tratamiento/prevencion de infeccion por malaria. Se describen también composiciones, vacunas y kits que comprenden dicho vector vírico. En un aspecto, se emplea un vector vírico C7 sintético. El vector vírico C7 puede coadministrarse o coformularse con un antígeno de la malaria tal como RTS,S, opcionalmente en presencia de un coadyuvante, por ejemplo, que comprende 3D-MPL y/o una saponina tal como QS21.A C7 replication-deficient ape adenoviral vector encoding a protein comprising P. falciparum CS protein or a fragment thereof for example as shown in SEQ ID NO: 1 or SEQ ID NO: 3. Also procedures for preparing said viral vector and the use of the viral vector in the treatment / prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect, a synthetic C7 viral vector is employed. The viral vector C7 can be co-administered or co-formulated with a malaria antigen such as RTS, S, optionally in the presence of an adjuvant, for example, comprising 3D-MPL and / or a saponin such as QS21.

ARP080105281A 2007-12-06 2008-12-04 MALARIA VACCINE USING RECOMBINANT ADENOVIRAL VECTORS AR069568A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
AR069568A1 true AR069568A1 (en) 2010-02-03

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105281A AR069568A1 (en) 2007-12-06 2008-12-04 MALARIA VACCINE USING RECOMBINANT ADENOVIRAL VECTORS

Country Status (20)

Country Link
EP (1) EP2227550A2 (en)
JP (1) JP2011505796A (en)
KR (1) KR20100108544A (en)
CN (1) CN101939438A (en)
AR (1) AR069568A1 (en)
AU (1) AU2008333208A1 (en)
BR (1) BRPI0819889A2 (en)
CA (1) CA2707245A1 (en)
CL (1) CL2008003614A1 (en)
CO (1) CO6300795A2 (en)
CR (1) CR11537A (en)
DO (1) DOP2010000164A (en)
IL (1) IL205953A0 (en)
MA (1) MA32003B1 (en)
MX (1) MX2010006207A (en)
PE (1) PE20091106A1 (en)
TW (1) TW200938633A (en)
UY (1) UY31510A1 (en)
WO (1) WO2009071613A2 (en)
ZA (1) ZA201003851B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (en) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Application of FGL2 protein as malaria infection marker

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
NZ539509A (en) * 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
AU2003298361B2 (en) * 2002-12-17 2009-05-14 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
ATE449105T1 (en) * 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio CHIMPANZEE ADENOVIRUS VACCINE CARRIAGE
JP5108521B2 (en) * 2004-10-14 2012-12-26 クルセル ホランド ベー ヴェー Malaria primary immunization / boost vaccine
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
AU2007276217B2 (en) * 2006-07-18 2013-08-29 Glaxosmithkline Biologicals S.A. Vaccines for malaria
AU2008223951B2 (en) * 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
ZA201003851B (en) 2012-11-28
MA32003B1 (en) 2011-01-03
CN101939438A (en) 2011-01-05
CL2008003614A1 (en) 2010-01-15
IL205953A0 (en) 2010-11-30
CA2707245A1 (en) 2009-06-11
PE20091106A1 (en) 2009-08-24
BRPI0819889A2 (en) 2015-06-16
UY31510A1 (en) 2009-08-03
TW200938633A (en) 2009-09-16
WO2009071613A3 (en) 2009-08-13
MX2010006207A (en) 2010-10-04
KR20100108544A (en) 2010-10-07
CO6300795A2 (en) 2011-07-21
EP2227550A2 (en) 2010-09-15
WO2009071613A2 (en) 2009-06-11
DOP2010000164A (en) 2010-07-31
JP2011505796A (en) 2011-03-03
AU2008333208A1 (en) 2009-06-11
CR11537A (en) 2010-08-18

Similar Documents

Publication Publication Date Title
MX347997B (en) Newcastle disease virus vectored avian vaccines.
EA201170812A1 (en) METHODS AND COMPOSITIONS FOR USING A VACCINE AGAINST COCKDIOSIS
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
PE20161560A1 (en) PCSK9 VACCINE
ES2673556T3 (en) Vaccines for HSV-2
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
PE20080428A1 (en) VACCINES FOR MALARIA
WO2006115843A3 (en) Nipah virus vaccines
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
AR093712A1 (en) IMMUNOGEN COMPOSITION, VACCINE, USE AND PROCEDURE FOR PREVENTION OR TREATMENT
BRPI0606189A2 (en) composition, vaccine and method for protecting a porcine animal from infection with a prrs virus, transfected host cell, method for making a genetically modified and attenuated prrs virus
CL2012000447A1 (en) Composition or vaccine comprising a recombinant avian paramyxovirus 8 (apmv-8) viral vector; method of producing said vector; and use to prepare medicament useful for inducing an immune response.
AR069568A1 (en) MALARIA VACCINE USING RECOMBINANT ADENOVIRAL VECTORS
BR112012021650A2 (en) "attenuated recombinant parvovirus, vaccine for the protection of animals against parvovirus infection, method for obtaining a recombinant parvovirus, and use of a vaccine."
WO2011056721A3 (en) Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
PE20170429A1 (en) VACCINE IN RECOMBINANT VECTOR OF AVIAN ADENOVIRUS SEROTYPE 9
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
WO2006007555A3 (en) Rotavirus antigens
TW200637573A (en) Peptide for delivery of mucosal vaccines
CO2017005830A2 (en) Vaccine compositions for dengue virus
PH12020551944A1 (en) Reverse peptide vaccine
WO2013171661A3 (en) Adjuvant formulations and methods
WO2009077744A3 (en) Vaccines for brucellosis
BR112014001287A2 (en) feline leukemia virus recombinant vaccine containing optimized feline leukemia virus envelope gene
WO2009005917A3 (en) Methods of treating measles infectious disease in mammals

Legal Events

Date Code Title Description
FA Abandonment or withdrawal